


30 October 2024



VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Group")

Director/PDMR Shareholding

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that Paul McGreevy, Non-Executive Chairman, has today purchased 116,519 ordinary shares of 0.3p each in the Company ("Ordinary Shares") at a price of 42.9 pence per Ordinary Share.

Following this purchase, Mr McGreevy beneficially holds 806,385 Ordinary Shares representing approximately 0.63 per cent. of the Company's issued share capital.

For further information, please contact:

Venture Life Group PLC	+44 (0) 1344 578004
Jerry Randall, Chief Executive Officer	
Daniel Wells, Chief Financial Officer	
 Cavendish Capital Markets Limited (Nomad and Broker)	+44 (0) 20 7397 8900
Michael Johnson (Sales)	
Stephen Keys / Camilla Hume (Corporate Finance)	

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, Earol for ear wax removal, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the Company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Paul McGreevy
2	Reason for the notification	
a)	Position/status	Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform	

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Venture Life Group plc					
b)	LEI	213800S8CZUPLAB2KC70					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.3p each in Venture Life Group plc					
	Identification code	GB00BFPM8908					
b)	Nature of the transaction	Purchase of ordinary shares					
c)	Price(s) and volume(s)	<table><tr><th>Price</th><th>Volume</th></tr><tr><td>42.9p</td><td>116,519</td></tr></table>	Price	Volume	42.9p	116,519	
Price	Volume						
42.9p	116,519						
d)	Aggregated information	n/a					
	- Aggregated volume						
	- Price						
e)	Date of the transaction	30 October 2024					
f)	Place of the transaction	London Stock Exchange					

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFIFILIVIS